Spruce Biosciences (SPRB) is nearing pivotal data releases from its ongoing clinical trials of Tildacerfont, an investigational therapy for Congenital Adrenal Hyperplasia.
Tildacerfont is a non-steroidal, oral second-generation CRF1 receptor antagonist, being developed to treat patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.